Allez Health develops an investigational continuous glucose monitoring (CGM) biosensor platform that aims to lower cost while improving performance and user experience. The company reports seven issued patents and over 40 pending patent applications. It has run more than 80 clinical studies aggregating over 1,500 users and completed a pivotal study in 120 insulin users. Allez Health plans to use new capital to support regulatory approval filings and to scale manufacturing and distribution arrangements. The sensor remains an investigational device and is not yet cleared or approved by the U.S. FDA or other regulatory authorities. Leadership emphasizes bringing an affordable, reliable CGM sensor to market for diabetes and broader wellness users.

Total raised

$60M

Funding rounds

1

Latest round

Series A

Latest activity

May 2024